11 December 2018 - New Zealand medicinal cannabis-based products company NUBU Pharmaceuticals says the passing of The
Misuse of Drugs (Medical Cannabis) Amendment Bill today is a welcome step forward in addressing patient need in New
Zealand.
NUBU CEO Mark Dye says “The passing of the Bill is a much needed advancement and will greatly improve accessibility of
medicinal cannabis products for New Zealanders.
“The public has been calling for better access to medicinal cannabis for a long time now, and the passing of the Bill is
a great first step in achieving this.
“NUBU was founded on a goal to help people in need access cannabis-based products without having to turn to the black
market. Now the Bill has passed we can really get underway in creating products that will help many people, both in New
Zealand and overseas,” says Dye.
In October, NUBU announced an exclusive distribution agreement with one of Europe’s leading cannabinoid-based
pharmaceutical companies, MGC Pharmaceuticals. The company is now in the final stages of securing a Licence to Deal in
Controlled Drugs from the Ministry of Health.
Now the Bill has passed, NUBU is focussed on plans to create its own cannabis products and to build an energy-efficient
glasshouse and state-of-the-art manufacturing facility.
As well as creating products for the local market, NUBU plans to develop a range of New Zealand made ‘value-add’
cannabis products to export to consumers in Europe and North America.
“We see huge opportunity for New Zealand with regards to cannabis.
“We are in talks with some of New Zealand’s leading brands and exporters in developing a range of organic CBD-based
“value-add” products.
“Cannabis is already commoditised, so as a company we have been focusing on what we can make here in New Zealand, that
no one else in the world can. Our product pipeline is incredibly exciting, and our international partners can’t wait for
our New Zealand made product to come online.
“Our aim is to make organic, sustainable cannabis-based premium products to share with New Zealand and the world.
“And the great thing is, when we do, everyone wins – the patients will win, the country will win and the industry will
thrive,” says Dye.
NUBU has enlisted a consultancy firm in Germany to ensure its manufacturing facility will be built to EU GMP standards –
the highest in the world.
ENDS